Biotechnology Innovation Operations Venture Capitalist 
Harvard Business Review
FEBRUARY 17, 2011
Venture capitalists are increasingly interested in emerging markets, and in working with local funds based in those markets (despite the fact that reverse innovation in venture capital seems counterintuitive). Many current therapeutic innovations require iterative feedback from the clinic to the lab and back again.
Harvard Business Review
MAY 2, 2011
Without operating in the former, they won't be able to attain economies of scale; sans the latter, they're unlikely to continue developing state-of-the-art technologies. Last year, at the World Economic Forum's annual meeting in China, we spoke with one of the country's most celebrated scientists, entrepreneurs, and venture capitalists.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Harvard Business Review
JUNE 16, 2016
The Institute for Applied Cancer Science at MD Anderson (IACS) is exploring revolutionary new cures and the National Network for Manufacturing Innovation (NNMI) is working to revive the US production capacity. Innovating the Innovation Process. “But here, we can operate within the time frame of the next coffee break.”
Harvard Business Review
OCTOBER 26, 2011
Many venture capitalists are limiting their investments to the "demand-side" — aimed at reducing energy use — rather than investing in startups trying to change the way we produce energy. Their behavior displays promising parallels to the early days of the biotechnology industry.
Harvard Business Review
FEBRUARY 3, 2015
Make you more innovative. Uzzi and another colleague, Jarrett Spiro, also discovered that this pattern held across sectors as disparate as the Broadway musical industry and biotechnology. The sidebar “The Innovator’s Network Dilemma” presents convincing data that bears out this observation.
Expert insights. Personalized for you.
15 
Let's personalize your content